If you think you’re the right fit for a GLP-1 agonist medication, we don’t recommend seeking out a proclaimed “natural” solution. Alternatively, talk to a health professional about your options.

For decades, researchers from all obesity-related disciplines have been observing the escalating prevalence of people living ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

BOULDER, CO / ACCESSWIRE / November 14, 2024 / Informa Market's New Hope Network and Nutrition Business Journal (NBJ) unveil ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

Natural body mass homeostasis is best achieved by eating a diet rich in plant-derived fibre, and low in saturated fats and highly processed carbohydrates.

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... and tirzepatide (branded as Mounjaro and ...